KRAS and colorectal carcinoma: Furthermore, extracellular vesicle DNA (evDNA) has demonstrated a 6.67% higher sensitivity than circulating free DNA (cfDNA) in detecting KRAS G12D and G13D mutations in the plasma of CRC patients.